ResearcherGuiyang Medical UniversityActive in the last 2 years

Chao Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8525-5920; OpenAlex author ID A5100582950. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 5

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 2

INHBA promotes chemoresistance in pancreatic cancer by enhancing CTPS1 stability and mediating pyrimidine metabolism. Last author DOI 10.1186/s12935-025-03984-8 ↗
High expression of syndecan-4 is related to clinicopathological features and poor prognosis of pancreatic adenocarcinoma. Last author DOI 10.1186/s12885-022-10128-y ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Dijie Zheng · 2 shared papers, 2022–2025 · strength 0.41
- Paper INHBA promotes chemoresistance in pancreatic cancer by enhancing CTPS1 stability and mediating pyrimidine metabolism. DOI 10.1186/s12935-025-03984-8 ↗
- Paper High expression of syndecan-4 is related to clinicopathological features and poor prognosis of pancreatic adenocarcinom… DOI 10.1186/s12885-022-10128-y ↗
Xinghao Sun · 1 shared paper, 2025 · strength 0.24
- Paper INHBA promotes chemoresistance in pancreatic cancer by enhancing CTPS1 stability and mediating pyrimidine metabolism. DOI 10.1186/s12935-025-03984-8 ↗
Zhiwei He · 1 shared paper, 2025 · strength 0.24
- Paper INHBA promotes chemoresistance in pancreatic cancer by enhancing CTPS1 stability and mediating pyrimidine metabolism. DOI 10.1186/s12935-025-03984-8 ↗
Kun Cai · 1 shared paper, 2022 · strength 0.17
- Paper High expression of syndecan-4 is related to clinicopathological features and poor prognosis of pancreatic adenocarcinom… DOI 10.1186/s12885-022-10128-y ↗
Yufei Zhu · 1 shared paper, 2022 · strength 0.17
- Paper High expression of syndecan-4 is related to clinicopathological features and poor prognosis of pancreatic adenocarcinom… DOI 10.1186/s12885-022-10128-y ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.